Th17 Inflammatory Pathway Therapeutics Markets Report


This report examines the therapeutic products and strategies that are being employed to improve outcomes by modulating the intracellular production of inflammatory mediators.



Immune‐mediated inflammatory diseases (IMIDs) is a term that encompasses a number of common, chronic and complex disorders, characterized by a dysregulation of the normal immune response which leads to inflammation in target organs and, usually, systemic effects as well. Examples include type 1 diabetes (T1D), Crohn’s disease (CD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS) and psoriasis.